Skip to main content
SpringerLink
Log in

Outcome of Patients with Aggressive Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Pseudomyxoma peritonei (PMP) is a rare disease with an incidence rate of approximately 1 per million a year. During the past few years, there has been a survival benefit for these patients treated by complete cytoreduction and perioperative chemotherapy. Better survival rates were found in the adenomucinosis group than the carcinomatosis group. The purpose of our study was to analyze the outcome and the prognosis factors of only high-grade PMP.

Methods

We selected 38 patients from a prospective database of 59 with high-grade PMP from appendiceal origin who were treated by cytoreduction surgery and HIPEC at the Hospital University Reina Sofia (Cordoba, Spain) between 1998 and July 2012. Clinical, surgical, analytical, radiological, and histological data were obtained prospectively. Survival curves were calculated using the Kaplan–Meier method, a univariate analysis was performed and the log rank-test was used to analyze the effects of several clinical and pathologic factors on overall survival (OS) and disease-free survival (DFS).

Results

Median follow-up time was 32 months (range, 2–170). Median age at diagnosis was 57 years (range, 32–77). In 89.5 % of patients, optimal cytoreduction CC-0 (57.9 %) and CC-1 (31.6 %) was achieved. In the remaining 10.5 %, cytoreduction was classified as CC-2. The median PCI score was 21 (range, 4–38). Morbidity complications ≥Grade 3 in the CTCAE v 3.0 classification was 18.4 %. One patient died 45 days postsurgery. Median OS at the end of follow-up was 36 months (range, 9–83); overall 5-year survival rate was 58.7 %. In the univariate analysis for OS, significant values were obtained for lymph-node involvement and suboptimal cytoreduction. The 5-year OS was 64.5 % when an optimal cytoreduction was achieved. Median DFS was 36 months (17–54); 3-year DFS rate was 49.1 %. Neoadjuvant therapy did not affect the survival of these patients; there was no difference in the 5-year OS (43 % vs. 75 %, p = 0.068).

Conclusions

In aggressive PMP, cytoreduction with peritonectomy procedure plus HIPEC is a safe procedure that suggests an improvement to the survival rates. Because optimal cytoreduction is a primary prognostic factor for survival rates, this procedure would have to be performed in an experienced center with a low morbidity. Neoadjuvant chemotherapy has not demonstrated benefits in these patients and further research will be required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN (2007) Survival analysis of Pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 245:104–109

    Article  PubMed  Google Scholar 

  2. Moran B, Baratti D, Yan TD, Kasamura S, Deraco M (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (Pseudomyxoma peritonei). J Surg Oncol 98:277–282

    Article  PubMed  Google Scholar 

  3. Sugarbaker PH (1995) Peritonectomy procedure. Ann Surg 221:29–42

    Article  PubMed  CAS  Google Scholar 

  4. Ronnett BM, Kurman RJ, Zahn CM et al (1995) Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 26:509–524

    Article  PubMed  CAS  Google Scholar 

  5. Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early and long-term outcome data of patients with Pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456

    Article  PubMed  Google Scholar 

  6. Bruin SC, Verwaal VJ, Vincent A, van’t Veer LJ, van Velthuysen ML (2010) A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin. Ann Surg Oncol 17:2330–2340

    Article  PubMed  Google Scholar 

  7. Sorensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky K, Larsen SG (2012) Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei. EJSO 06.552

  8. Andreasson H, Graf W, Nygren P, Glimelius B, Mahteme H (2012) Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei. Eur J Surg Oncol 38(10):962–968

    Google Scholar 

  9. Sugarbaker PH, Chang D (1999) Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6:727–731

    Article  PubMed  CAS  Google Scholar 

  10. Arjona-Sánchez A, Muñoz Casares FC, Rufián Peña S, Diaz Nieto, Casado Adam A, Rubio Perez MJ, Ortega Salas R (2011) Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre. Clin Transl Oncol 13:261–267

    Article  PubMed  Google Scholar 

  11. Jaquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58

    Google Scholar 

  12. Muñoz-Casares FC, Rufián S, Rubio MJ, Lizárraga E, Díaz-Iglesias C, Aranda E, Ciria R, Muntané J, Barrios P, Torres-Melero J, González-Moreno S, González-Bayón L, Camps B, Bretcha P, Farré J, Ortega-Pérez G, Gómez Portilla A (2007) Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol 9:652–662

    Article  PubMed  Google Scholar 

  13. Younan R, Kusamura S, Baratti D, Cloutier AS, Deraco M (2008) Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol 98(4):253

    Article  PubMed  Google Scholar 

  14. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO et al (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219:112–119

    Article  PubMed  CAS  Google Scholar 

  15. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG (2005) Long-term survival following treatment of Pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241:300–308

    Article  PubMed  Google Scholar 

  16. Gonzalez-Moreno S, Sugarbaker PH (2004) Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 91:304–311

    Article  PubMed  CAS  Google Scholar 

  17. Elias D, Honoré C, Ciuchendea R, Billard V, Raynard B, Lo Dico R, Dromain C, Duvillard P, Goeré D (2008) Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 95:1164–1171

    Article  PubMed  CAS  Google Scholar 

  18. Cioppa T, Vaira M, Bing C, D’amico S, Bruscino A, de Simone M (2008) Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from Pseudomyxoma peritonei. World J Gastroenterol 14:6817–6823

    Article  PubMed  Google Scholar 

  19. Yan TD, Links M, Xu ZY, Kam C, Glenn D, Morris DL (2006) Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 93:1270–1276

    Article  PubMed  CAS  Google Scholar 

  20. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH (2003) Appendiceal mucinous neoplasm’s: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 27:1089

    Article  PubMed  Google Scholar 

  21. Guo AT, Li YM, Wei LX (2012) Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors. World J Gastroenterol 18(24):3081–3088

    Article  PubMed  Google Scholar 

  22. Elias D, Gilly F, Quenet F, Bereder JM, Sideris L, Mansvelt B, Lorimier G, Glehen O (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. EJSO 36:456

    Article  PubMed  CAS  Google Scholar 

  23. Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR (2006) Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 30(5):551–559

    Article  PubMed  Google Scholar 

  24. Carr NJ, Finch J, Ilesley IC et al (2012) Pathology and prognosis in Pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 10.1136/jclinpath-2012-200843

  25. Ronnet BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH (2001) Patients with Pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85–91

    Article  Google Scholar 

  26. Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M (2009) Pseudomyxoma peritonei. Ann Surg 249:243–249

    Article  PubMed  Google Scholar 

  27. Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH (2004) Utility of CEA y CA 19.9 tumors makers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 87:162–166

    Article  PubMed  Google Scholar 

  28. Van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarían cáncer: pharmacokinetics and cisplatin-DNA adducts formation in patients. Eur J Cancer 34:148–154

    Article  PubMed  Google Scholar 

  29. Shapiro JF, Chase JL, Wolff RA et al (2010) Modern systemic chemotherapy in surgically unresectable neoplasm of appendiceal origin: a single institution experience. Cancer 116:316–322

    Article  PubMed  Google Scholar 

  30. Sugarbaker PH, Bijelic L, Chang D et al (2010) Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritomucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 102:576–581

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, H.U. Reina Sofia, Cordoba, Spain

    Alvaro Arjona-Sanchez, Francisco Cristobal Muñoz-Casares, Angela Casado-Adam, Juan Manuel Sánchez-Hidalgo, Maria Dolores Ayllon Teran, Rafael Orti-Rodriguez, Ana Cristina Padial-Aguado, Javier Medina-Fernández & Sebastián Rufián-Peña

  2. Department of Pathology, H.U. Reina Sofia, Cordoba, Spain

    Rosa Ortega-Salas

  3. Department of Oncology, H.U. Reina Sofia, Cordoba, Spain

    Gema Pulido-Cortijo & Auxiliadora Gómez-España

Authors
  1. Alvaro Arjona-Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco Cristobal Muñoz-Casares
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Casado-Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Manuel Sánchez-Hidalgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Dolores Ayllon Teran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rafael Orti-Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ana Cristina Padial-Aguado
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Javier Medina-Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rosa Ortega-Salas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gema Pulido-Cortijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Auxiliadora Gómez-España
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sebastián Rufián-Peña
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alvaro Arjona-Sanchez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arjona-Sanchez, A., Muñoz-Casares, F.C., Casado-Adam, A. et al. Outcome of Patients with Aggressive Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. World J Surg 37, 1263–1270 (2013). https://doi.org/10.1007/s00268-013-2000-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-013-2000-2

Keywords

Search

Navigation